TNFRSF17 and plasma cell myeloma: Real world data have revealed that the median overall survival for patients progressing on DARA is approximately one year, but this may change with the introduction of novel therapies targeting B-cell maturation antigen (BCMA) and other targets on myeloma cells [14,15,16].